AU2001287850A1 - Iron compositions - Google Patents

Iron compositions

Info

Publication number
AU2001287850A1
AU2001287850A1 AU2001287850A AU8785001A AU2001287850A1 AU 2001287850 A1 AU2001287850 A1 AU 2001287850A1 AU 2001287850 A AU2001287850 A AU 2001287850A AU 8785001 A AU8785001 A AU 8785001A AU 2001287850 A1 AU2001287850 A1 AU 2001287850A1
Authority
AU
Australia
Prior art keywords
iron compositions
compositions
iron
hydroxypyrone
bloodstream
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287850A
Inventor
Michael Arthur Stockham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitra Pharmaceuticals Ltd
Original Assignee
Vitra Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0022881A external-priority patent/GB0022881D0/en
Priority claimed from GB0107031A external-priority patent/GB0107031D0/en
Application filed by Vitra Pharmaceuticals Ltd filed Critical Vitra Pharmaceuticals Ltd
Publication of AU2001287850A1 publication Critical patent/AU2001287850A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compositions in solid form, such as powders, comprising a mixture of a ferrous salt and a hydroxypyrone maybe used to increase the level of iron in a patient's bloodstream or to treat and/or prevent gastrointestinal infection.
AU2001287850A 2000-09-19 2001-09-10 Iron compositions Abandoned AU2001287850A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0022881 2000-09-19
GB0022881A GB0022881D0 (en) 2000-09-19 2000-09-19 Iron compositions
GB0107031A GB0107031D0 (en) 2001-03-21 2001-03-21 Iron compositions
GB0107031 2001-03-21
PCT/GB2001/004052 WO2002024196A1 (en) 2000-09-19 2001-09-10 Iron compositions

Publications (1)

Publication Number Publication Date
AU2001287850A1 true AU2001287850A1 (en) 2002-04-02

Family

ID=26245020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287850A Abandoned AU2001287850A1 (en) 2000-09-19 2001-09-10 Iron compositions

Country Status (8)

Country Link
US (1) US7135196B2 (en)
EP (1) EP1318804B1 (en)
AT (1) ATE282411T1 (en)
AU (1) AU2001287850A1 (en)
CA (1) CA2421410C (en)
DE (1) DE60107272T2 (en)
ES (1) ES2236300T3 (en)
WO (1) WO2002024196A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932648B2 (en) * 2006-01-30 2015-01-13 Globoasia, Llc Method of selecting phosphate binder and its uses thereof
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
WO2007136845A2 (en) 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. Low-dose doxepin for treatment of sleep disorders in elderly patients
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
WO2007136741A2 (en) * 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. N-desmethyl-doxepin and methods of using the same to treat sleep disorders
CA2687118A1 (en) 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100105614A1 (en) * 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US20110077200A1 (en) 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
US20090074862A1 (en) * 2007-04-13 2009-03-19 Luigi Schioppi Low-dose doxepin formulations and methods of making and using the same
GB0808835D0 (en) * 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
EP3091974B1 (en) 2014-01-06 2020-04-01 Shield TX (UK) Limited Dosage regimen of ferric trimaltol
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
GB2553099A (en) * 2016-08-19 2018-02-28 Shield Tx Uk Ltd Use
MX2020000691A (en) * 2017-07-20 2020-07-29 Nutreco Ip Assets Bv Trace mineral composition.
CN112203639A (en) * 2018-05-16 2021-01-08 法国诗华大药厂 Veterinary composition and its use for controlling iron deficiency in non-human mammals
CN115177625A (en) * 2022-06-28 2022-10-14 金陵药业股份有限公司 Carboxyl ferric maltose pharmaceutical composition and preparation method thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3130204A (en) * 1962-02-07 1964-04-21 Pfizer & Co C Preparation of gamma-pyrones
DE1518098A1 (en) * 1963-09-19 1969-04-10 Pfizer & Co C Process for the preparation of pyromeconic acid derivatives
SE322866B (en) * 1966-12-15 1970-04-20 Astra Ab
GB1178874A (en) 1967-08-02 1970-01-21 Mallinckrodt Chemical Works A Stable Pharmaceutical Composition
US4018907A (en) * 1975-08-25 1977-04-19 General Foods Corporation Coloring food with iron-complexes
US4279936A (en) * 1979-09-24 1981-07-21 William Underwood Company Maltol treated canned meat process
GR78491B (en) * 1982-03-24 1984-09-27 Nat Res Dev
DE3365971D1 (en) * 1982-03-24 1986-10-16 Nat Res Dev Pharmaceutical compositions containing a complex of iron with n-substituted 3-hydroxypyrid-2-one or -4-one derivatives
EP0107458B1 (en) * 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
GB8308054D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308055D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
USRE34313E (en) * 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8325494D0 (en) * 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4912118A (en) * 1983-09-23 1990-03-27 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) * 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
GB8410290D0 (en) * 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
US5177068A (en) * 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
GB8410289D0 (en) 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
GB8606913D0 (en) * 1986-03-20 1986-04-23 Hider R C Treatment of sickle cell disease
IT1204069B (en) 1986-05-30 1989-03-01 Menarini Sas USE OF THE PHARMACEUTICAL FORM FOR ORAL USE OF FERROUS SALTS THAT CAN BE USED IN THERAPY IN THE FORM OF IRON DEFICIENCY ANEMIA
JPH0367565A (en) 1989-08-07 1991-03-22 Kansai Paint Co Ltd Iron-enriched food
GB9209078D0 (en) * 1992-04-27 1992-06-10 Hider Robert C Pharmaceutical compositions
GB9217099D0 (en) 1992-08-12 1992-09-23 British Tech Group Pharmaceutical compositions
WO1996041627A2 (en) 1995-06-10 1996-12-27 Vitra Pharmaceuticals Ltd Iron compounds, compositions, methods of making the same and uses thereof
GB9621273D0 (en) 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method

Also Published As

Publication number Publication date
EP1318804B1 (en) 2004-11-17
CA2421410C (en) 2009-11-10
WO2002024196A1 (en) 2002-03-28
CA2421410A1 (en) 2002-03-28
DE60107272D1 (en) 2004-12-23
DE60107272T2 (en) 2005-10-27
EP1318804A1 (en) 2003-06-18
ES2236300T3 (en) 2005-07-16
US20040029853A1 (en) 2004-02-12
ATE282411T1 (en) 2004-12-15
US7135196B2 (en) 2006-11-14

Similar Documents

Publication Publication Date Title
AU2001287850A1 (en) Iron compositions
BE2011C028I2 (en) Macrocyclic analogs and methods of their use and preparation
MXPA02012937A (en) Combinations of active ingredients, which exhibit insecticidal and acaricidal properties.
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
UA66856C2 (en) Thienopyrimidines, a method for the preparation thereof, a pharmaceutical composition and a method for the preparation thereof
DE69633178D1 (en) Iron compounds, compositions, methods of preparation and uses thereof
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
MXPA04001256A (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof.
WO2002011747A3 (en) Transglutaminase for inhibiting angiogenesis
TR200402070T4 (en) Cyclobutene-dione derivatives and their use in the treatment of arteriosclerosis
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
ATE222118T1 (en) PHARMACEUTICAL COMBINATION PREPARATIONS CONTAINING ERYTHROPOIETIN AND IRON PREPARATIONS
MXPA02007903A (en) USE OF 2minus;METHYLminus;THIAZOLIDINminus;2,4minus;DICARBOXYLIC ACID (2minus;MTDC) AND OR PHYSIOLOGICALLY COMPATIBLE SALTS FOR TREATING AND OR PREVENTING CANCERS.
WO1999011256A8 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
GR1003490B (en) Novel pharmaceutical compositions comprising a salt of paraxetine
EP1303300A4 (en) Compositions and methods for treatment of candidiasis
AUPQ866500A0 (en) Therapeutic compounds and methods
MD980129A (en) Antiherpetic remedy
MXPA02012165A (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites.
ZA200201384B (en) 1,4-dioxacycloalkane-2-one and 1,4-dioxacyloalkene-2-one.
WO2001060344A3 (en) Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections
MXPA05003633A (en) 2" oxo-voruscharin and derivatives thereof.
IL150979A0 (en) 9-alkylamino-1-nitroacridine derivatives